PL407163A1 - Biomarkery transkryptomiczne, sposób określania i zastosowanie biomarkerów transkryptomicznych do stratyfikacji indywidualnego ryzyka rozwoju pozawałowej niewydolności serca - Google Patents

Biomarkery transkryptomiczne, sposób określania i zastosowanie biomarkerów transkryptomicznych do stratyfikacji indywidualnego ryzyka rozwoju pozawałowej niewydolności serca

Info

Publication number
PL407163A1
PL407163A1 PL407163A PL40716314A PL407163A1 PL 407163 A1 PL407163 A1 PL 407163A1 PL 407163 A PL407163 A PL 407163A PL 40716314 A PL40716314 A PL 40716314A PL 407163 A1 PL407163 A1 PL 407163A1
Authority
PL
Poland
Prior art keywords
transcriptomic biomarkers
stratification
heart failure
transcriptomic
biomarkers
Prior art date
Application number
PL407163A
Other languages
English (en)
Other versions
PL228091B1 (pl
Inventor
Beata Burzyńska
Monika Góra
Agata Maciejak
Dorota Tułacz
Marek Kiliszek
Marcin Michalak
Grzegorz Opolski
Krzysztof Matlak
Sławomir Dobrzycki
Original Assignee
Instytut Biochemii I Biofizyki Polskiej Akademii Nauk
Warszawski Uniwersytet Medyczny
Uniwersytet Medyczny W Białymstoku
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Biochemii I Biofizyki Polskiej Akademii Nauk, Warszawski Uniwersytet Medyczny, Uniwersytet Medyczny W Białymstoku filed Critical Instytut Biochemii I Biofizyki Polskiej Akademii Nauk
Priority to PL407163A priority Critical patent/PL228091B1/pl
Priority to EP15712187.2A priority patent/EP3105350B1/en
Priority to PCT/IB2015/000141 priority patent/WO2015121737A2/en
Publication of PL407163A1 publication Critical patent/PL407163A1/pl
Publication of PL228091B1 publication Critical patent/PL228091B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Przedmiotem wynalazku są biomarkery transkryptomiczne do stratyfikacji indywidualnego ryzyka rozwoju pozawałowej niewydolności serca odpowiadające podwyższonemu poziomowi ekspresji co najmniej dwóch genów z grupy transkryptów obejmującej: FNM1, RNASE1, TIMP1, JDP2, lub co najmniej jednego genu z grupy transkryptów obejmującej: FMN1, RNASE1, JDP2.
PL407163A 2014-02-12 2014-02-12 Zestaw biomarkerów transkryptomicznych do zastosowania w stratyfikacji indywidualnego ryzyka rozwoju pozawałowej niewydolnosci serca, sposób diagnozowania ryzyka wystapienia u pacjenta pozawałowej niewydolnosci serca i zastosowanie biomarkerów do diagnostyki in vitro PL228091B1 (pl)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL407163A PL228091B1 (pl) 2014-02-12 2014-02-12 Zestaw biomarkerów transkryptomicznych do zastosowania w stratyfikacji indywidualnego ryzyka rozwoju pozawałowej niewydolnosci serca, sposób diagnozowania ryzyka wystapienia u pacjenta pozawałowej niewydolnosci serca i zastosowanie biomarkerów do diagnostyki in vitro
EP15712187.2A EP3105350B1 (en) 2014-02-12 2015-02-12 Transcriptomic biomarkers, method for determination thereof and use of transcriptomic biomarkers for individual risk assessment of developing post-infarction heart failure
PCT/IB2015/000141 WO2015121737A2 (en) 2014-02-12 2015-02-12 Transcriptomic biomarkers, method for determination thereof and use of trnascriptomic biomarkers for individual risk assessment of developing post-infraction heart failure

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL407163A PL228091B1 (pl) 2014-02-12 2014-02-12 Zestaw biomarkerów transkryptomicznych do zastosowania w stratyfikacji indywidualnego ryzyka rozwoju pozawałowej niewydolnosci serca, sposób diagnozowania ryzyka wystapienia u pacjenta pozawałowej niewydolnosci serca i zastosowanie biomarkerów do diagnostyki in vitro

Publications (2)

Publication Number Publication Date
PL407163A1 true PL407163A1 (pl) 2015-08-17
PL228091B1 PL228091B1 (pl) 2018-02-28

Family

ID=52737367

Family Applications (1)

Application Number Title Priority Date Filing Date
PL407163A PL228091B1 (pl) 2014-02-12 2014-02-12 Zestaw biomarkerów transkryptomicznych do zastosowania w stratyfikacji indywidualnego ryzyka rozwoju pozawałowej niewydolnosci serca, sposób diagnozowania ryzyka wystapienia u pacjenta pozawałowej niewydolnosci serca i zastosowanie biomarkerów do diagnostyki in vitro

Country Status (3)

Country Link
EP (1) EP3105350B1 (pl)
PL (1) PL228091B1 (pl)
WO (1) WO2015121737A2 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201902077D0 (en) * 2019-02-14 2019-04-03 Univ College Dublin Nat Univ Ireland Dublin Biomarkers
CN110478484B (zh) * 2019-08-08 2021-10-26 中山大学 抑制jdp2表达的物质在制备抗肿瘤药物中的应用
DE102020205364B4 (de) 2020-04-28 2022-01-20 Universität Rostock Verfahren zur Überwachung des Verlaufs einer Kardiomyozyten-Transplantation und Methode zur Bestimmung, ob ein Proband für einer Kardiomyozyten-Transplantation geeignet ist
CN111593121A (zh) * 2020-07-07 2020-08-28 吉林大学 G0s2基因在急性心肌梗死风险预测标记物中的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007272521A1 (en) * 2006-07-11 2008-01-17 Musc Foundation For Research Development Predicting heart failure following myocardial infarction by protease and protease inhibitor profiling
BRPI0920069A8 (pt) * 2008-10-30 2017-10-03 Centre De Rech Public De La Sante Biomarcadores
WO2013148316A1 (en) * 2012-03-29 2013-10-03 Biogen Idec Ma Inc. Biomarkers for use in integrin therapy applications

Also Published As

Publication number Publication date
WO2015121737A3 (en) 2015-11-26
WO2015121737A2 (en) 2015-08-20
WO2015121737A4 (en) 2016-02-04
EP3105350A2 (en) 2016-12-21
EP3105350B1 (en) 2019-04-10
PL228091B1 (pl) 2018-02-28

Similar Documents

Publication Publication Date Title
EA201890013A1 (ru) Способы получения tcr гамма дельтат-клеток
PH12017500669A1 (en) Compositions and methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
BR112019010565A2 (pt) aplicação viral de neoantígenos
WO2012106718A3 (en) Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
EA201891192A1 (ru) Средства и способы лечения миопатий, связанных с титином, и других титинопатий
EP3311299A4 (en) METHODS OF PREDICTING PATHOGENICITY OF GENETIC SEQUENCE VARIANTS
BR112016007401A2 (pt) métodos e processos para avaliação não invasiva das variações genéticas
SG10201900323SA (en) Method for inducing t cells for cell-based immunotherapy from pluripotent stem cells
BR112016026950A2 (pt) composições de rnai para angiotensinogênio (agt) e métodos de uso das mesmas
SG10201910479UA (en) Method for diagnosis and prognosis of chronic heart failure
BR112016016916A2 (pt) método de tratamento de angiodema hereditário (hae)
BR112014028881A2 (pt) populações de células, banco de células, métodos de obtenção de uma população de células, métodos de identificação de um fator, métodos de seleção, métodos de fornecimento de terapia, populações de hepatócitos e método de obtenção de células
BR112017012142A2 (pt) método para predição da resposta a agentes terapêuticos para o câncer de mama e método de tratamento de câncer de mama
BR112016027222A2 (pt) anticorpos isolados, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de tratamento de um indivíduo com um câncer, de inibição da proliferação de uma célula, de detecção de gpc3 humano e de detecção de um câncer
MX2016004418A (es) Stent de puntal delgado de polimero bioabsorbible con una alta resistencia radial y a la fatiga y metodo para la fabricacion del mismo.
MX2024009873A (es) Construcciones de arni para inhibir expresion de asgr1 y metodos para su uso.
CY1123677T1 (el) Απομονωση αυθεντικων παγκρεατικων προγονικων κυτταρων
CY1123144T1 (el) Επαγωγη καρδιακης αναγεννησης μe microrna
PL407163A1 (pl) Biomarkery transkryptomiczne, sposób określania i zastosowanie biomarkerów transkryptomicznych do stratyfikacji indywidualnego ryzyka rozwoju pozawałowej niewydolności serca
NZ730124A (en) A method of predicting risk of recurrence of cancer
BR112018009097A8 (pt) spodoptera frugiperda resistente a vip3a
EP4335502A3 (en) Modified u6 promoter system for tissue specific expression
EP3305307A4 (en) PROMOTER OF MIGRATION OF PLURIPOTENT STEM CELLS
MX2019001946A (es) Marcador para celulas madre neurales.
MX2015016114A (es) Biomarcadores de expresion de gen y sus usos para aplicacion de diagnosis y prognosis en pacientes potencialmente en necesidad de tratamiento de inhibidor de histona desacetilasa (hdac).